"Maintenance Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatment designed to help prevent a relapse of a disease following the successful primary treatments (INDUCTION CHEMOTHERAPY and CONSOLIDATION CHEMOTHERAPY) with a long-term low-dose drug therapy.
| Descriptor ID |
D060046
|
| MeSH Number(s) |
E02.319.509
|
| Concept/Terms |
Maintenance Chemotherapy- Maintenance Chemotherapy
- Chemotherapies, Maintenance
- Chemotherapy, Maintenance
- Maintenance Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Maintenance Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Maintenance Chemotherapy".
This graph shows the total number of publications written about "Maintenance Chemotherapy" by people in this website by year, and whether "Maintenance Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 4 | 6 |
| 2016 | 1 | 4 | 5 |
| 2017 | 2 | 6 | 8 |
| 2018 | 5 | 4 | 9 |
| 2019 | 2 | 4 | 6 |
| 2020 | 3 | 9 | 12 |
| 2021 | 4 | 6 | 10 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Maintenance Chemotherapy" by people in Profiles.
-
Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol. 2024 Nov; 190:255-261.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
-
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2424-2432.
-
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024 May; 24(5):e196-e204.
-
Significant erythroid megaloblastic changes in patients treated with allopurinol during maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 11; 70(11):e30631.
-
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 12 01; 40(34):3952-3964.
-
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147.
-
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 06 30; 386(26):2482-2494.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.